Sculptor Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sculptor Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,600	Closed	-$1.21M	–	348
2023 Q4	$1.21M	Hold	12,600	–	–	0.03%	178
2023 Q3	$1.11M	Hold	12,600	–	–	0.02%	183
2023 Q2	$1.09M	Hold	12,600	–	–	0.02%	180
2023 Q1	$1.23M	Buy	+12,600	New	+$1.31M	0.03%	238
2020 Q2	–	Sell	-13,800	Closed	-$1.17M	–	286
2020 Q1	$1.17M	Hold	13,800	–	–	0.02%	151
2019 Q4	$1.17M	Hold	13,800	–	–	0.01%	204
2019 Q3	$930K	Buy	+13,800	New	+$1.06M	0.01%	231

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sculptor Capital's BMRN Position: Q4 2023 in Review

Sculptor Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 18,799 shares — an estimated $1.66M sold.

Sculptor Capital first reported a position in BMRN in Q1 2015 and held it in 8 quarters. The position peaked at $74.4M in Q1 2015. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Sculptor Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Sculptor Capital sold 18,799 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $1.66M.
Sculptor Capital first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Sculptor Capital's BioMarin Pharmaceuticals position peaked at $74.4M in Q1 2015.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Sculptor Capital's 13F filing for Q4 2023, filed 14 Feb 2024.